Sotera cleared to sell its full mobile-monitor system

Following its April go-ahead on Sotera Wireless’ ViSi mobile monitor, a stand-alone device for continuous observation of vital signs, the FDA has extended the 510(k) approval to the full ViSi system.

San Diego-based Sotera said the added feature is a wireless transmission function that will allow the devices to send data via WiFi to computers and mobile devices, as well as to hospitals’ EMR systems.

The company said it designed the product line, which consists of a device worn on the wrist and various non-invasive sensors placed elsewhere on the body, for use in ambulatory care settings. It added that it is testing sensing technologies for future versions.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.